Effectiveness of REGEN-COV combination monoclonal antibody infusion to reduce the risk of COVID-19 hospitalization in pregnancy: a retrospective cohort study

Abstract

Pregnancy is a risk factor for severe COVID-19.1 The REGEN-COV combination monoclonal antibody infusion, efficaciously reduced COVID-19 hospitalization in nonpregnant patients who were at risk of severe disease but did not meet the admission criteria.2 When REGEN-COV was issued emergency use authorization in the summer of 2021, national organizations endorsed the use of antispike monoclonal antibodies in pregnant patients, despite their exclusion from efficacy trials.3 We hypothesized that REGEN-COV infusion reduces the risk of COVID-19 hospitalization among pregnant patients diagnosed during alpha- and delta-predominant COVID-19 waves.